Silvana Libertini

Novartis (Switzerland) — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

21h-index1.5kcitations44works5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(12), Cancer-related Molecular Pathways(10), CRISPR and Genetic Engineering(9), CAR-T cell therapy research(9), Microtubule and mitosis dynamics(6)

Publications44 total

Summary of major conclusions from the 8th International Workshop on Genotoxicity Testing (IWGT), Ottawa, Canada
2025Open Access
Isolated oral CD30+/CD4+ CAR+ T cell lymphoma in long-term remission after radiotherapy
Molecular Therapy·2025Open Access
SACF and GILA assays on AML12 cells show limited predictive value for mouse liver genotoxicity
Toxicology and Applied Pharmacology·2025· 1 cited
PET-based tracking of CAR T cells and viral gene transfer using a cell surface reporter that binds to lanthanide complexes
Nature Biomedical Engineering·2025· 5 citedOpen Access
Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec
Molecular Therapy·2025· 3 cited
Aggressive Lymphoma after CD19 CAR T-Cell Therapy
New England Journal of Medicine·2024· 32 citedOpen Access
Genotoxicity evaluation of gene therapies: A report from the International Workshop on Genotoxicity Testing (<scp>IWGT</scp>) 2022
Environmental and Molecular Mutagenesis·2024· 1 citedOpen Access
Genotoxicity evaluation of gene therapies: highlights from IWGT 2022
2024Open Access
Detection of residual pluripotent stem cells in cell therapy products utilizing droplet digital PCR: an international multisite evaluation study
Stem Cells Translational Medicine·2024· 3 citedOpen Access
Improving the Assessment of Risk Factors Relevant to Potential Carcinogenicity of Gene Therapies: A Consensus Article
Human Gene Therapy·2024· 6 citedOpen Access
DTPA-Receptor – A novel reporter gene system for the specific and sensitive PET imaging of CAR-T cells and AAV transduced cells
2023Open Access
Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec
Molecular Therapy·2023· 23 citedOpen Access
Identification of marker genes to monitor residual iPSCs in iPSC-derived products
Cytotherapy·2022· 21 cited
Evaluation of two in vitro assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cells
Molecular Therapy — Methods & Clinical Development·2021· 17 citedOpen Access
In vitro transformation assays for non-clinical safety assessment of CRISPR/Cas9 genome-edited cells
The Novartis Repository (Novartis)·2021
Safety of cell therapy products: in-vitro methods to assess the tumorigenicity of human cell-based therapeutic products
Cytotherapy·2020· 3 cited
Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider
Cytotherapy·2019· 150 citedOpen Access
In situ detection of DNA double strand breaks by immunofluorescent gamma-H2AX staining in mice exposed to multiwalled carbon nanotubes
Toxicology Letters·2019
Table of Contents
Kidney International·2019Open Access
Generation of renal Epo-producing cell lines by conditional gene tagging reveals rapid HIF-2 driven Epo kinetics, cell autonomous feedback regulation, and a telocyte phenotype
Kidney International·2018· 52 cited
page 1 of 3Next →

Frequent Co-authors

Giuseppe Portella(14), David A. Gillespie(7), Owen J. Sansom(6), Antonella Abagnale(6), Ginevra Botta(6), Myriam Lemmens(6), Paolo Chieffi(5), Carmela Passaro(5), Giuseppe Perruolo(4), Ulrike Naumann(4), Giancarlo Troncone(3), Spiros Linardopoulos(3), Alfredo Fusco(3), Yoji Sato(3), Lucilia Pereira Mouriès(3), Patrizia Cammareri(3), David F. Vincent(3), Rachel A. Ridgway(3), Dimitris Athineos(3), Angela McHugh(3)